Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Summit Therapeutics' ivonescimab performed well in a phase 3 study. The cancer drug candidate is licensed from a Chinese ...

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

Biopharmaceutical giant Merck (NYSE: MRK) has broken ground on a $1 billion pharmaceutical manufacturing facility in ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

The American Association for Cancer Research’s annual conference continued Tuesday with Marengo Therapeutics making progress ...

We recently published a list of Billionaire Cliff Asness’ 10 Stock Picks with Huge Upside Potential. In this article, we are ...

Three stocks that offer yields of more than 3% and which are trading near their 52-week lows today are Merck ( MRK -0.81%), ...